Barasertib (AZD1152-HQPA)

For research use only.

Catalog No.S1147 Synonyms: AZD2811, INH-34

81 publications

Barasertib (AZD1152-HQPA) Chemical Structure

CAS No. 722544-51-6

Barasertib (AZD1152-HQPA, AZD2811, INH-34) is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay, ~3700 fold more selective for Aurora B over Aurora A. Phase 1.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 168 In stock
USD 120 In stock
USD 210 In stock
USD 387 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Barasertib (AZD1152-HQPA) has been cited by 81 publications

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Description Barasertib (AZD1152-HQPA, AZD2811, INH-34) is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay, ~3700 fold more selective for Aurora B over Aurora A. Phase 1.
Targets
Aurora B [1]
(Cell-free assay)
0.37 nM
In vitro

AZD1152 displays >3000-fold selectivity for Aurora B as compared with Aurora A which has an IC50 of 1.368 μM. AZD1152 has even less activity against 50 other serine-threonine and tyrosine kinases including FLT3, JAK2, and Abl. AZD1152 inhibits the proliferation of hematopoietic malignant cells such as HL-60, NB4, MOLM13, PALL-1, PALL-2, MV4-11, EOL-1, THP-1, and K562 cells with IC50 of 3-40 nM, displaying ~100-fold potency than another Aurora kinase inhibitor ZM334739 which has IC50 of 3-30 μM. AZD1152 inhibits the clonogenic growth of MOLM13 and MV4-11 cells with IC50 of 1 nM and 2.8 nM, respectively, as well as the freshly isolated imatinib-resistant leukemia cells with IC50 values of 1-3 nM, more significantly compared with bone marrow mononuclear cells with IC50 values of >10 nM. AZD1152 induces accumulation of cells with 4N/8N DNA content, followed by apoptosis in a dose- and time-dependent manner. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LNCaP M{[2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrSNFRoOC13MECgcm0> NVXWRWpIPDkEoHi= MnzpTWM2OD1{NTDuUS=> M4DxUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OlU6Lz5{NUK3O|Y2QTxxYU6=
LNCaP NE\rUHZCeG:ydH;zbZMhSXO|YYm= M1uxWFAuPTByIH7N M13h[lQ5yqCq Ml7PbY5lfWOnczDhdI9xfG:2aXOgZ4VtdCCmZXH0bEB1cHKxdXfoJINie3Cjc3WtN{B2eHKnZ4XsZZRqd25? NWrGOXh7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|c3PTlpPkK1Nlc4PjV7PD;hQi=>
LNCaP MUDGeY5kfGmxbjDBd5NigQ>? M2DDVVUxKG6P MWe0PEBp MlW4bY5lfWOnczDtbYNzd263Y3zlbUB4cXSqIHHu[ZVo\W6rYzDt[YNp[W6rc32= NETC[Go9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3O|Y2QSd-MkWyO|c3PTl:L3G+
Ramos NGfr[WVHfW6ldHnvckBCe3OjeR?= NV7XUHp{PTByIH7N NEfRSXUxNTd{IHi= Mn\vbY5pcWKrdIOgRZVzd3KjIFKgb4lv[XOn MmHaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|N{G0OFYoRjJzM{exOFQ3RC:jPh?=
Daudi  NYjWO3pPTnWwY4Tpc44hSXO|YYm= M4rUfVUxOCCwTR?= MV6wMVczKGh? NEWzeWZqdmirYnn0d{BCfXKxcnGgRkBscW6jc3W= M4DLSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{exOFQ3Lz5{MUO3NVQ1PjxxYU6=
L540 NYPqclRyTnWwY4Tpc44hSXO|YYm= NVLke2Q{PTByIH7N M1zl[|AuPzJiaB?= Ml7qbY5pcWKrdIOgRZVzd3KjIFKgb4lv[XOn M{HFUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{exOFQ3Lz5{MUO3NVQ1PjxxYU6=
BJAJ MoX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfYOnM2ODBibl2= Mlf4NE04OiCq MoX6bY5pcWKrdIOgZ4VtdCCpcn;3eIghe2mpbnnmbYNidnSueR?= NGPYfHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO3NVQ1Pid-MkGzO|E1PDZ:L3G+
Ramos M1uxVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEH5cZg2ODBibl2= M1jCOFAuPzJiaB?= NF7WRm1qdmirYnn0d{Bk\WyuIHfyc5d1cCC|aXfubYZq[2GwdHz5 NXvUToZoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzO|E1PDZpPkKxN|cyPDR4PD;hQi=>
Raji MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4joeVUxOCCwTR?= NUXLNFVYOC15MjDo MUnpcohq[mm2czDj[YxtKGe{b4f0bEB{cWewaX\pZ4FvfGy7 NIPM[lk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO3NVQ1Pid-MkGzO|E1PDZ:L3G+
Daudi  M1f0PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLLOVAxKG6P NHL3U3ExNTd{IHi= MVjpcohq[mm2czDj[YxtKGe{b4f0bEB{cWewaX\pZ4FvfGy7 NXrPOIFCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzO|E1PDZpPkKxN|cyPDR4PD;hQi=>
L428 MoXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13VcFUxOCCwTR?= NYnGWopHOC15MjDo NW\IeVRqcW6qaXLpeJMh[2WubDDndo94fGh? NXX2b5hVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzO|E1PDZpPkKxN|cyPDR4PD;hQi=>
KM-H2 NHHHcmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWeyeoFiPTByIH7N MlixNE04OiCq NYnHZXBicW6qaXLpeJMh[2WubDDndo94fGh? NXfkbnZGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzO|E1PDZpPkKxN|cyPDR4PD;hQi=>
HDLM-2 MnrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnYOVAxKG6P NGnmVJAxNTd{IHi= NETCfHhqdmirYnn0d{Bk\WyuIHfyc5d1cA>? Mn3pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|N{G0OFYoRjJzM{exOFQ3RC:jPh?=
L450 MmLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jucVUxOCCwTR?= MoT2NE04OiCq NHHqN49qdmirYnn0d{Bk\WyuIHfyc5d1cA>? MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN5MUS0Okc,OjF|N{G0OFY9N2F-
BJAJ MVHBdI9xfG:|aYOgRZN{[Xl? M{X2dlUxOCCwTR?= MYmwMVczKGh? M{\FRolv\HWlZYOgZZBweHSxc3nzJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXy MoDUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|N{G0OFYoRjJzM{exOFQ3RC:jPh?=
Ramos NGfVO4NCeG:ydH;zbZMhSXO|YYm= MW[1NFAhdk1? MUKwMVczKGh? MojNbY5lfWOnczDhdI9xfG:|aYOgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK= MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN5MUS0Okc,OjF|N{G0OFY9N2F-
Raji MYHBdI9xfG:|aYOgRZN{[Xl? NFOyOm82ODBibl2= NYrxW5N1OC15MjDo NHTBdIVqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> M{\SR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{exOFQ3Lz5{MUO3NVQ1PjxxYU6=
Daudi  MkW5RZBweHSxc3nzJGF{e2G7 NIH3PHQ2ODBibl2= MoSzNE04OiCq MVfpcoR2[2W|IHHwc5B1d3OrczDpckBiKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NEe3ZlA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO3NVQ1Pid-MkGzO|E1PDZ:L3G+
L428 NXTJb4lISXCxcITvd4l{KEG|c3H5 NHv2O5o2ODBibl2= M4DlfVAuPzJiaB?= Mmq4bY5lfWOnczDhdI9xfG:|aYOgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK= MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN5MUS0Okc,OjF|N{G0OFY9N2F-
KM-H2 MX3BdI9xfG:|aYOgRZN{[Xl? NVPXWoQyPTByIH7N MoWyNE04OiCq NXzsSpZ7cW6mdXPld{BieG:ydH;zbZMhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> M3rrS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{exOFQ3Lz5{MUO3NVQ1PjxxYU6=
HDLM-2 M{\jSWFxd3C2b4Ppd{BCe3OjeR?= M3q5b|UxOCCwTR?= M134XVAuPzJiaB?= M1fSRYlv\HWlZYOgZZBweHSxc3nzJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXy NHzNbZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO3NVQ1Pid-MkGzO|E1PDZ:L3G+
L450 NYf1WpIySXCxcITvd4l{KEG|c3H5 M3HIVFUxOCCwTR?= NFzjT4cxNTd{IHi= NFHBdJlqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> NV30fY51RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzO|E1PDZpPkKxN|cyPDR4PD;hQi=>
SW620 M1\Rd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3y1cmVEPTB;MUFCtVIvOSCwTR?= NUDmZ3VVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGyOFUxQTBpPkKxNlQ2ODlyPD;hQi=>
HCT116 MnfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHiSWM2OD1zMdMxN{4{KG6P NU\aWI9YRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGyOFUxQTBpPkKxNlQ2ODlyPD;hQi=>
MDA-MB-435 MmX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHB[2lPOC1zMECwNEBvVQ>? MV:yMVUh\A>? NVHU[ooyTE2VTx?= M2\LNmlEPTB;MUK1JI5O MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF5NUmyOkc,OjBzN{W5NlY9N2F-
MDA-MB-468 NYG5bHNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWmwMVExODByIH7N M1HN[VIuPSCm NEXZNIRFVVOR M2HHbGlEPTB;MUSgcm0> M4DmRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUe1PVI3Lz5{MEG3OVkzPjxxYU6=
MDA-MB-231 MoDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTWNE0yODByMDDuUS=> MUSyMVUh\A>? Mke3SG1UVw>? MkTiTWM2OD1zMEWgcm0> MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF5NUmyOkc,OjBzN{W5NlY9N2F-
BT474 NWTMfZdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLmS2Y5OC1zMECwNEBvVQ>? NV3FVHVuOi13IHS= MmrvSG1UVw>? MWDJR|UxRThibl2= NYLEbnluRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxO|U6OjZpPkKwNVc2QTJ4PD;hQi=>
MDA-MB-361 Mk[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknuNE0yODByMDDuUS=> NHTMUmkzNTViZB?= NUjzZVg5TE2VTx?= M1;zZWlEPTB;N{Cgcm0> MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF5NUmyOkc,OjBzN{W5NlY9N2F-
HER18 NUDtbYVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXewMVExODByIH7N NEHENGQzNTViZB?= NYXidHpYTE2VTx?= NUL3[3VnUUN3ME2yNEBvVQ>? NHTQS4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG3OVkzPid-MkCxO|U6OjZ:L3G+
HER18 MmmyRZBweHSxc3nzJGF{e2G7 MmrSNVAxKG6P MkDVNE8zPC92ODDo NH7qbWxFVVOR NUm0cm1JcW6mdXPld{BieG:ydH;zbZMh[W6mIILl[JVk\XNiY3zvco9o\W6rYzDwc5RmdnSrYXy= NF;Rfmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG3OVkzPid-MkCxO|U6OjZ:L3G+
MDA-MB-231 MXjBdI9xfG:|aYOgRZN{[Xl? NWjWeWQ2OTB3IH7N MYCwM|I1NzR6IHi= NEj1VHhFVVOR MXHpcoR2[2W|IHHwc5B1d3OrczDhcoQhemWmdXPld{BkdG:wb3flcolkKHCxdHXueIlidA>? NGTTVVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG3OVkzPid-MkCxO|U6OjZ:L3G+
JHH-1 NX7YbYNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWKwMlPjiJNzMECwxsBvVQ>? NWntflVIPzJiaB?= NXzRNGFbTUN3ME2xO{41yrFzLkCgcm0> M1rhblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUGzPVM2Lz5zOUmxN|k{PTxxYU6=
JHH-2 NWTYeoFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIX5V4wxNjQkgKOxNFAxyqCwTR?= NH;rSZA4OiCq MlzaSWM2OD1{MUiuNOKyOTBwODDuUS=> NGTMR2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUmxN|k{PSd-MUm5NVM6OzV:L3G+
JHH-4 NEKzd5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HSOVAvO+LCk{GwNFDDqG6P NGLoPXo4OiCq NV7H[XA4TUN3ME2xOVUvPsLzMU[uPEBvVQ>? MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTlzM{mzOUc,OTl7MUO5N|U9N2F-
HuH-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3r3eFAvO+LCk{GwNFDDqG6P MlLOO|IhcA>? M1\jfmVEPTB;MkeuN:KyPS5yIH7N M3L3e|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUGzPVM2Lz5zOUmxN|k{PTxxYU6=
HuH-6 M3TZXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33RRVAvO+LCk{GwNFDDqG6P M3znV|czKGh? NGjIWpBGSzVyPUOuO:KyOC54IH7N MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTlzM{mzOUc,OTl7MUO5N|U9N2F-
HuH-7 MnvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnMNE4{6oDVMUCwNOKhdk1? NXnqZWtGPzJiaB?= NUfvS|ZWTUN3ME22MljDuTBwMzDuUS=> MnrYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7MUO5N|UoRjF7OUGzPVM2RC:jPh?=
HLE M2Lmb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXWwMlPjiJNzMECwxsBvVQ>? NFnOS284OiCq MnLsSWM2OD12NT65xtE3NjRibl2= M4rQRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUGzPVM2Lz5zOUmxN|k{PTxxYU6=
HLF M3XTS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU[wMlPjiJNzMECwxsBvVQ>? NHfLSXg4OiCq MXLFR|UxRTF{Nj6xxtEyOi5{IH7N M4Lld|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUGzPVM2Lz5zOUmxN|k{PTxxYU6=
PLC/PRF/5 NYHJTYY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYWwMlPjiJNzMECwxsBvVQ>? NGfVRpQ4OiCq MX7FR|UxRTd4LkpCtVkvQSCwTR?= MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTlzM{mzOUc,OTl7MUO5N|U9N2F-
SK-Hep1 MoWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHndXQxNjQkgKOxNFAxyqCwTR?= MYq3NkBp NWPK[IFTTUN3ME2yNU46yrFzLkKgcm0> MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTlzM{mzOUc,OTl7MUO5N|U9N2F-
Hep3B NHriNpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\SNE4{6oDVMUCwNOKhdk1? NITveWk4OiCq MUjFR|UxRTdwNtMxNU4zKG6P M{fDVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUGzPVM2Lz5zOUmxN|k{PTxxYU6=
HepG2 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTrNE4{6oDVMUCwNOKhdk1? NUHSOIp{PzJiaB?= NFjzNVVGSzVyPUG0MlfDuTFwNzDuUS=> M2rUeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUGzPVM2Lz5zOUmxN|k{PTxxYU6=
Ramos NVrYZ5FXSXCxcITvd4l{KEG|c3H5 Mn;rNlUwPTBxMUCwJI5O NX;h[IRoPDhiaB?= MWjpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iC2aHWgZ4xm[X[nZDDmc5JueyCxZjDQRXJRKGGwZDDjZZNx[XOnIEO= NUewO2pWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm4NlMyPjhpPkG5PFI{OTZ6PD;hQi=>
Daudi  MUHBdI9xfG:|aYOgRZN{[Xl? MVOyOU82OC9zMECgcm0> MoLYOFghcA>? NXfUdXBRcW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[geIhmKGOuZXH2[YQh\m:{bYOgc4YhWEGUUDDhcoQh[2G|cHHz[UA{ NHXUS2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUiyN|E3QCd-MUm4NlMyPjh:L3G+
BALM-14 MVfBdI9xfG:|aYOgRZN{[Xl? M{i1VVEzNjVxMkWvOVAhdk1? MnHIOFghcA>? NEXpeWdqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjD0bIUh[2ynYY\l[EBnd3KvczDv[kBRSVKSIHHu[EBk[XOyYYPlJFM> MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTh{M{G2PEc,OTl6MkOxOlg9N2F-
BALM-27 MkC3RZBweHSxc3nzJGF{e2G7 MofUNVIvPS9{NT:1NEBvVQ>? MmS4OFghcA>? M2DxeYlv[3KnYYPld{B1cGVibHX2[Yx{KG:oIITo[UBkdGWjdnXkJIZwem2|IH;mJHBCWlBiYX7kJINie3Cjc3WgNy=> M{XiZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OEKzNVY5Lz5zOUiyN|E3QDxxYU6=
NB4 MnTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17N[VAvODFxMD6xM|Eh|ryP NEnLZ401QCCq NWqxOVVEcW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfS=> MnTUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh|Nke0PFQoRjF6M{[3OFg1RC:jPh?=
HeLa M1T0TmZ2dmO2aX;uJGF{e2G7 M2Lpb|EhfU1? NG\YV3gzPCCqcoO= NGnwV4hKdmirYnn0bY9vKG:oIHH1do9z[SCEIHH1eI9xcG:|cHjvdplt[XSrb36gbY4hcHWvYX6gTIVN[SClZXzsd{BifCBzIIXNJIFnfGW{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5R1cW6p MoHvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4OES1OFkoRjJyNki0OVQ6RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
AURKB / pSer10 Histone H3 / TP53 / CDKN1A / MYCN; 

PubMed: 26497213     


Downstream effects of barasertib-induced AURKB inhibition on histone H3 phosphorylation and TP53 protein levels in IMR5 and SK-N-BE (2c) as indicated after 24h (left) and 48h (right). TP53 and its downstream effector CDKN1A were up-regulated by barasertib䲧疝Ỵ疞㧀疜膉痘 瘿⟸෕ᾰƌ෕Ð 㺣痖帉痖Ѐ瑖堘𢡄빢᎒

p53 / p21 / p-p38 / p38 ; 

PubMed: 24782314     


U2OS cells were treated with 50 nm or 100 nm AZD1152 for 24 h. p21, p38, p-p38, and p53 levels were determined by immunoblotting β-actin served as a loading control.

26497213 24782314
Immunofluorescence
p21 ; 

PubMed: 24782314     


U2OS cells were treated as in H. Levels of p21 were analyzed by immunostaining. DNA was counterstained with Hoechst 33258.

24782314
Growth inhibition assay
Cell viability ; 

PubMed: 26497213     


Dose response curves to barasertib at 72h of incubation normalized to the DMSO control sample (mean ± SD, n = 5). The inset depicts the normalized AUCs of each response curve. 

26497213
In vivo Administration of AZD1152 (25 mg/kg) alone markedly suppresses the growth of MOLM13 xenografts, confirmed by the observation of necrotic tissue with infiltration of phagocytic cells. [1] In addition, AZD1152 (10-150 mg/kg/day) significantly inhibits the growth of a variety of human solid tumor xenografts, including colon, breast, and lung cancers, in a dose-dependent manner. [2]

Protocol

Cell Research:[1]
- Collapse
  • Cell lines: HL-60, NB4, MOLM13, PALL-2, MV4-11, EOL-1, and K562 cells
  • Concentrations: Dissolved in DMSO, final concentrations ~100 nM
  • Incubation Time: 24 or 48 hours
  • Method: Cells are exposed to various concentrations of AZD1152 for 24 or 48 hours. Cell proliferation is measured by 3H-thymidine uptake (isotope added 6 hours before harvest), and the concentration that induced 50% growth inhibition (IC50) is calculated from dose-response curves. Cell cycle analysis is performed by flow cytometry. Cell apoptosis is measured by annexin V–FITC apoptosis detection kit.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: Female immune-deficient BALB/c nude mice subcutaneously injected with MOLM13 cells
  • Dosages: 5 or 25 mg/kg
  • Administration: Intraperitoneal injection 4 times a week or every another day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 102 mg/mL (200.96 mM)
Water Insoluble
Ethanol '3 mg/mL
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+40% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
7mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 507.56
Formula

C26H30FN7O3

CAS No. 722544-51-6
Storage powder
in solvent
Synonyms AZD2811, INH-34
Smiles CCN(CCCOC1=CC2=C(C=C1)C(=NC=N2)NC3=NNC(=C3)CC(=O)NC4=CC(=CC=C4)F)CCO

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can you let me know what solvent I can use for Barasertib, cat # S1147, for in vivo use? (IP injection in mice)

  • Answer:

    S1147 Barasertib (AZD1152-HQPA) can be dissolved in 30% PEG400/0.5% Tween80/5% Propylene glycol at 30mg/ml as a clear solution. Usually, when prepare the solution, we will add organic solvents first, then add Tween 80, then water. But this compound can not dissolve in 30% PEG400/0.5% Tween80/5% Propylene glycol clearly. After water was added, it became a clear solution.

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Related Aurora Kinase Products

Tags: buy Barasertib (AZD1152-HQPA) | Barasertib (AZD1152-HQPA) supplier | purchase Barasertib (AZD1152-HQPA) | Barasertib (AZD1152-HQPA) cost | Barasertib (AZD1152-HQPA) manufacturer | order Barasertib (AZD1152-HQPA) | Barasertib (AZD1152-HQPA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID